Need help finding what you are looking for?
Contact Us
PUBLISHER: Market Research Future | PRODUCT CODE: 1457898
PUBLISHER: Market Research Future | PRODUCT CODE: 1457898
North America Pharmacokinetics and Pharmacodynamics Market Research Report Forecast to 2032
PUBLISHED:
PAGES: 105 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Market Overview
North America Pharmacokinetics and Pharmacodynamics Market is anticipated to register a significant CAGR of 7.09% by 2032. Pharmacokinetics (PK) and pharmacodynamics (PD) are two closely related branches of pharmacology that deal with the study of drugs and their effects on the body. Pharmacokinetics (PK) is the study of how the body handles a drug, from the time it is administered until it is eliminated. It encompasses the processes of absorption, distribution, metabolism, and excretion (ADME). Furthermore, pharmacodynamics (PD) is the study of the effects of drugs on the body. It investigates how drugs interact with molecular targets, such as receptors or enzymes, to produce their physiological effects. PD studies aim to characterize the relationship between drug concentration and its effect, including the onset, duration, and intensity of the effect.
The North America pharmacokinetics and pharmacodynamics market is predicted to expand due to the increasing prevalence of chronic diseases, advancements in technology and analytical techniques, and strong healthcare infrastructure. Additionally, the shortage of skilled and experienced professionals will provide growth opportunities for the market in the future. However, the growing popularity of personalized medicine might hamper the market's growth in the forecast period.
Market Segmentation
Based on service type, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmacokinetic services, pharmacodynamic services. pharmacokinetic services further segmented into drug absorption studies, drug distribution studies, drug metabolism studies, drug excretion studies, and others. pharmacodynamic services further segmented into receptor binding studies, biomarker analysis, and others.
Based on drug type, the North America pharmacokinetics and pharmacodynamics market has been segmented into small molecules and large molecules.
Based on application, the North America pharmacokinetics and pharmacodynamics market has been segmented into oncology, cardiovascular, infectious disease, neurology, immunology, and others.
Based on end user, the North America pharmacokinetics and pharmacodynamics market has been segmented into pharmaceutical and biotechnology companies, academic and research institutions, and others.
The North America pharmacokinetics and pharmacodynamics market is segmented into the US and Canada. The US held the largest market share of 82.34% based on region and Canada is anticipated to dominate the overall pharmacokinetics and pharmacodynamics market during the forecast period.
Major Players
The key players operating in the market are LGC Limited Eurofins Scientific, Charles River Laboratories, Evotec AG, SGS Societe Generale de Surveillance SA, LGC Limited, Eurofins Scientific, Charles River Laboratories, Evotec AG, and SGS Societe Generale de Surveillance SA.
TABLE OF CONTENTS
1EXECUTIVE SUMMARY
2MARKET INTRODUCTION
- 2.1DEFINITION
- 2.2SCOPE OF THE STUDY
- 2.3RESEARCH OBJECTIVE
- 2.4MARKET STRUCTURE
3RESEARCH METHODOLOGY
- 3.1OVERVIEW
- 3.2DATA FLOW
- 3.2.1DATA MINING PROCESS
- 3.3PURCHASED DATABASE:
- 3.4SECONDARY SOURCES:
- 3.4.1SECONDARY RESEARCH DATA FLOW:
- 3.5PRIMARY RESEARCH:
- 3.5.1PRIMARY RESEARCH DATA FLOW:
- 3.5.2PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.6APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1REVENUE ANALYSIS APPROACH
- 3.7DATA FORECASTING
- 3.7.1DATA FORECASTING TYPE
- 3.8DATA MODELING
- 3.8.1MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2DATA MODELING:
4MARKET DYNAMICS
- 4.1INTRODUCTION
- 4.2DRIVERS
- 4.2.1INCREASING PREVALENCE OF CHRONIC DISEASES
- 4.2.2ADVANCEMENTS IN TECHNOLOGY AND ANALYTICAL TECHNIQUES
- 4.2.3STRONG HEALTHCARE INFRASTRUCTURE
- 4.3RESTRAINTS
- 4.3.1SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS
- 4.4OPPORTUNITY
- 4.4.1GROWING POPULARITY OF PERSONALIZED MEDICINE
5MARKET FACTOR ANALYSIS
- 5.1VALUE CHAIN ANALYSIS
- 5.1.1CUSTOMER ACQUISITION (PREPURCHASE QUERY)
- 5.1.2SERVICE CUSTOMIZATION
- 5.1.3CUSTOMER PURCHASE SUPPORT
- 5.1.4CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
- 5.2PORTER'S FIVE FORCES MODEL
- 5.2.1THREAT OF NEW ENTRANTS
- 5.2.2BARGAINING POWER OF SUPPLIERS
- 5.2.3THREAT OF SUBSTITUTES
- 5.2.4BARGAINING POWER OF BUYERS
- 5.2.5INTENSITY OF RIVALRY
- 5.3IMPACT OF COVID-19 ON THE NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET
- 5.3.1OVERVIEW
- 5.3.2IMPACT ON PRICING
- 5.3.3IMPACT ON KEY PLAYERS
6NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE
- 6.1OVERVIEW
- 6.2PHARMACOKINETIC SERVICES
- 6.2.1DRUG ABSORPTION STUDIES
- 6.2.2DRUG DISTRIBUTION STUDIES
- 6.2.3DRUG METABOLISM STUDIES
- 6.2.4DRUG EXCRETION STUDIES
- 6.2.5OTHERS
- 6.3PHARMACODYNAMIC SERVICES
- 6.3.1RECEPTOR BINDING STUDIES
- 6.3.2BIOMARKER ANALYSIS
- 6.3.3OTHERS
7NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE
- 7.1OVERVIEW
- 7.2SMALL MOLECULES
- 7.3LARGE MOLECULES
8NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA
- 8.1OVERVIEW
- 8.2ONCOLOGY
- 8.3CARDIOVASCULAR
- 8.4INFECTIOUS DISEASES
- 8.5NEUROLOGY
- 8.6IMMUNOLOGY
- 8.7OTHERS
9NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER
- 9.1OVERVIEW
- 9.2PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
- 9.3ACADEMIC AND RESEARCH INSTITUTIONS
- 9.4OTHERS
10NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY
- 10.1OVERVIEW
- 10.2NORTH AMERICA
- 10.3US
- 10.4CANADA
11COMPETITIVE LANDSCAPE
- 11.1INTRODUCTION
- 11.2MARKET SHARE ANALYSIS, 2022
- 11.3COMPETITOR DASHBOARD
- 11.4PUBLIC PLAYERS STOCK SUMMARY
- 11.5COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12COMPANY PROFILES
- 12.1CREATIVE BIOARRAY
- 12.1.1COMPANY OVERVIEW
- 12.1.2FINANCIAL OVERVIEW
- 12.1.3PRODUCTS OFFERED
- 12.1.4KEY DEVELOPMENTS
- 12.1.5KEY STRATEGY
- 12.2QUANTICATE
- 12.2.1COMPANY OVERVIEW
- 12.2.2FINANCIAL OVERVIEW
- 12.2.3SERVICES OFFERED
- 12.2.4KEY DEVELOPMENTS
- 12.2.5KEY STRATEGY
- 12.3PACIFIC BIOLABS, INC.
- 12.3.1COMPANY OVERVIEW
- 12.3.2FINANCIAL OVERVIEW
- 12.3.3SERVICES OFFERED
- 12.3.4KEY DEVELOPMENTS
- 12.3.5KEY STRATEGIES
- 12.4ALLUCENT
- 12.4.1COMPANY OVERVIEW
- 12.4.2FINANCIAL OVERVIEW
- 12.4.3SERVICES OFFERED
- 12.4.4KEY DEVELOPMENTS
- 12.4.5SWOT ANALYSIS
- 12.4.6KEY STRATEGIES
- 12.5CHARLES RIVER LABORATORIES
- 12.5.1COMPANY OVERVIEW
- 12.5.2FINANCIAL OVERVIEW
- 12.5.3SERVICES OFFERED
- 12.5.4KEY DEVELOPMENTS
- 12.5.5SWOT ANALYSIS
- 12.5.6KEY STRATEGIES
- 12.6EVOTEC AG
- 12.6.1COMPANY OVERVIEW
- 12.6.2FINANCIAL OVERVIEW
- 12.6.3SERVICES OFFERED
- 12.6.4KEY DEVELOPMENTS
- 12.6.5SWOT ANALYSIS
- 12.6.6KEY STRATEGIES
- 12.7SGS SOCIETE GENERALE DE SURVEILLANCE SA.
- 12.7.1COMPANY OVERVIEW
- 12.7.2FINANCIAL OVERVIEW
- 12.7.3SERVICES OFFERED
- 12.7.4KEY DEVELOPMENTS
- 12.7.5KEY STRATEGIES
- 12.8LGC LIMITED
- 12.8.1COMPANY OVERVIEW
- 12.8.2FINANCIAL OVERVIEW
- 12.8.3SERVICES OFFERED
- 12.8.4KEY DEVELOPMENTS
- 12.8.5KEY STRATEGIES
- 12.9EUROFINS SCIENTIFIC
- 12.9.1COMPANY OVERVIEW
- 12.9.2FINANCIAL OVERVIEW
- 12.9.3SERVICES OFFERED
- 12.9.4KEY DEVELOPMENTS
- 12.9.5SWOT ANALYSIS
- 12.9.6KEY STRATEGIES
- 12.10CREATIVE BIOLABS
- 12.10.1COMPANY OVERVIEW
- 12.10.2FINANCIAL OVERVIEW
- 12.10.3SERVICES OFFERED
- 12.10.4KEY DEVELOPMENTS
- 12.10.5SWOT ANALYSIS
- 12.10.6KEY STRATEGIES
LIST OF TABLES
- TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT 29
- TABLE 2 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION) 44
- TABLE 3 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY COUNTRY, 2019-2032 (USD MILLION) 45
- TABLE 4 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE, 2019-2032 (USD MILLION) 46
- TABLE 5 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG ABSORPTION STUDIES, BY COUNTRY, 2019-2032 (USD MILLION) 46
- TABLE 6 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG DISTRIBUTION STUDIES, BY COUNTRY, 2019-2032 (USD MILLION) 46
- TABLE 7 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG METABOLISM STUDIES, BY COUNTRY, 2019-2032 (USD MILLION) 47
- TABLE 8 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR DRUG EXCRETION STUDIES, BY COUNTRY, 2019-2032 (USD MILLION) 47
- TABLE 9 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019-2032 (USD MILLION) 47
- TABLE 10 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY COUNTRY, 2019-2032 (USD MILLION) 48
- TABLE 11 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE, 2019-2032 (USD MILLION) 48
- TABLE 12 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR RECEPTOR BINDING STUDIES, BY COUNTRY, 2019-2032 (USD MILLION) 48
- TABLE 13 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2032 (USD MILLION) 49
- TABLE 14 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019-2032 (USD MILLION) 49
- TABLE 15 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE, 2019-2032 (USD MILLION) 51
- TABLE 16 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR SMALL MOLECULES, BY COUNTRY, 2019-2032 (USD MILLION) 52
- TABLE 17 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR LARGE MOLECULES, BY COUNTRY, 2019-2032 (USD MILLION) 52
- TABLE 18 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA, 2019-2032 (USD MILLION) 54
- TABLE 19 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR ONCOLOGY, BY COUNTRY, 2019-2032 (USD MILLION) 55
- TABLE 20 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR CARDIOVASCULAR, BY COUNTRY, 2019-2032 (USD MILLION) 55
- TABLE 21 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2032 (USD MILLION) 56
- TABLE 22 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR NEUROLOGY, BY COUNTRY, 2019-2032 (USD MILLION) 56
- TABLE 23 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR IMMUNOLOGY, BY COUNTRY, 2019-2032 (USD MILLION) 56
- TABLE 24 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019-2032 (USD MILLION) 57
- TABLE 25 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER, 2019-2032 (USD MILLION) 59
- TABLE 26 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2032 (USD MILLION) 60
- TABLE 27 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2032 (USD MILLION) 60
- TABLE 28 NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR OTHERS, BY COUNTRY, 2019-2032 (USD MILLION) 61
- TABLE 29 NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY, 2019-2032 (USD MILLION) 63
- TABLE 30 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION) 64
- TABLE 31 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE, 2019-2032 (USD MILLION) 65
- TABLE 32 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE, 2019-2032 (USD MILLION) 65
- TABLE 33 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY DRUG TYPE, 2019-2032 (USD MILLION) 65
- TABLE 34 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY THERAPEUTIC AREA, 2019-2032 (USD MILLION) 66
- TABLE 35 US: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY END USER, 2019-2032 (USD MILLION) 66
- TABLE 36 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2019-2032 (USD MILLION) 66
- TABLE 37 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACOKINETIC SERVICES, BY TYPE, 2019-2032 (USD MILLION) 67
- TABLE 38 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, FOR PHARMACODYNAMIC SERVICES, BY TYPE, 2019-2032 (USD MILLION) 67
- TABLE 39 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY DRUG TYPE, 2019-2032 (USD MILLION) 67
- TABLE 40 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY THERAPEUTIC AREA, 2019-2032 (USD MILLION) 68
- TABLE 41 CANADA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET BY END USER, 2019-2032 (USD MILLION) 68
- TABLE 42 PUBLIC PLAYERS STOCK SUMMARY 72
- TABLE 43 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 72
- TABLE 44 CREATIVE BIOARRAY: PRODCUTS OFFERED 74
- TABLE 45 QUANTICATE: SERVICES OFFERED 77
- TABLE 46 PACIFIC BIOLABS, INC.: SERVICES OFFERED 79
- TABLE 47 ALLUCENT: SERVICES OFFERED 82
- TABLE 48 CHARLES RIVER LABORATORIES: SERVICES OFFERED 86
- TABLE 49 EVOTEC AG: SERVICES OFFERED 89
- TABLE 50 SGS SOCIETE GENERALE DE SURVEILLANCE SA: SERVICE OFFERED 93
- TABLE 51 LGC LIMITED: SERVICES OFFERED 95
- TABLE 52 EUROFINS SCIENTIFIC: SERVICES OFFERED 98
- TABLE 53 CREATIVE BIOLABS: SERVICES OFFERED 101
LIST OF FIGURES
- FIGURE 1NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET: STRUCTURE16
- FIGURE 2NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET: MARKET GROWTH FACTOR
ANALYSIS (2022-2032)32
- FIGURE 3DRIVER IMPACT ANALYSIS (2023-2032)34
- FIGURE 4RESTRAINT IMPACT ANALYSIS (2022-2032)35
- FIGURE 5VALUE CHAIN ANALYSIS OF THE NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET37
- FIGURE 6PORTER'S FIVE FORCES ANALYSIS: NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET39
- FIGURE 7NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, SERVICE TYPE SEGMENT ATTRACTIVENESS,
2019-2032 (USD MILLION)
- FIGURE 8NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY SERVICE TYPE, 2022 & 2032 (USD MILLION)44
- FIGURE 9NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY SERVICE TYPE, 202245
- FIGURE 10NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, DRUG TYPE SEGMENT ATTRACTIVENESS,
2019-2032 (USD MILLION)
- FIGURE 11NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY DRUG TYPE, 2022 & 2032 (USD MILLION)51
- FIGURE 12NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY DRUG TYPE, 202252
- FIGURE 13NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, THERAPEUTIC AREA SEGMENT ATTRACTIVENESS, 2019-2032 (USD MILLION)53
- FIGURE 14NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY THERAPEUTIC AREA,
2022 & 2032 (USD MILLION)
- FIGURE 15NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY THERAPEUTIC AREA, 202255
- FIGURE 16NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, END USER SEGMENT ATTRACTIVENESS,
2019-2032 (USD MILLION)
- FIGURE 17NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY END USER, 2022 & 2032 (USD MILLION)59
- FIGURE 18NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY END USER, 202260
- FIGURE 19NORTH AMERICA MARKET ANALYSIS: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, 2019-2032 (USD MILLION)62
- FIGURE 20NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET, BY COUNTRY, 2022 & 2032 (USD MILLION)63
- FIGURE 21NORTH AMERICA: PHARMACOKINETICS AND PHARMACODYNAMICS MARKET SHARE (%), BY COUNTRY, 202264
- FIGURE 22NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET PLAYERS: COMPETITIVE ANALSIS, 202270
- FIGURE 23COMPETITOR DASHBOARD: NORTH AMERICA PHARMACOKINETICS AND PHARMACODYNAMICS MARKET71
- FIGURE 24ALLUCENT: SWOT ANALYSIS83
- FIGURE 25CHARLES RIVER LABORATORIES: FINANCIAL OVERVIEW SNAPSHOT86
- FIGURE 26CHARLES RIVER LABORATORIES: SWOT ANALYSIS87
- FIGURE 27EVOTEC AG: FINANCIAL OVERVIEW SNAPSHOT89
- FIGURE 28EVOTEC AG: SWOT ANALYSIS90
- FIGURE 29SGS SOCIETE GENERALE DE SURVEILLANCE SA: FINANCIAL OVERVIEW SNAPSHOT92
- FIGURE 30LGC LIMITED: FINANCIAL OVERVIEW SNAPSHOT95
- FIGURE 31EUROFINS SCIENTIFIC: FINANCIAL OVERVIEW SNAPSHOT98
- FIGURE 32EUROFINS SCIENTIFIC: SWOT ANALYSIS100
- FIGURE 33CREATIVE BIOLABS: SWOT ANALYSIS103
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.